View details of this raise on Seedstage

San Diego, CA

Developing gene therapies to address aging and chronic diseases.

• Innovative Gene Therapy: Rejuvenate Bio develops one-shot gene therapies targeting aging and chronic diseases.
• Proven Preclinical Results: Therapies have shown efficacy in reversing cardiac damage and extending lifespan in animals.
• Strategic Partnerships: The company has secured partnerships in the animal health sector, providing funding and validation.
• Cost-Effective Manufacturing: Proprietary manufacturing process reduces costs, making therapies more accessible.
• Transition to Human Trials: Current fundraising supports the move from animal models to human clinical trials.

Rejuvenate Bio is advancing its gene therapy platform to address age-related decline and chronic diseases. The company is leveraging its expertise in genetics and synthetic biology to develop therapies that target the root causes of aging. Their approach involves a one-time injection that has shown promising results in preclinical models, including reversing cardiac damage and extending lifespan in animals. The company has secured significant partnerships in the animal health sector, which provide both funding and validation for their technology.

The current fundraising aims to support the transition of these therapies from animal models to human clinical trials. Rejuvenate Bio’s platform has been backed by substantial non-dilutive funding and venture capital, highlighting its potential impact on the healthcare industry. The company’s innovative manufacturing process reduces costs, making these therapies more accessible. With a focus on both animal and human health, Rejuvenate Bio is positioned to make significant strides in the treatment of cardiometabolic and aging-related diseases.

Company Info

Rejuvenate Bio develops gene therapies to reverse aging and chronic diseases, validated in animal models and advancing towards human applications.

Rejuvenate Bio focuses on developing innovative gene therapies aimed at reversing age-related decline and chronic diseases. Their approach involves a one-time injection that reprograms the body to restore youthful function, with proven efficacy in animal models such as dogs and mice. The company leverages partnerships in the animal health sector to generate revenue and support the development of their therapies, which are designed to be both effective and affordable.

The company’s platform includes liver-directed gene therapy and epigenetic reprogramming, targeting cardiovascular, metabolic, and neurodegenerative diseases. Rejuvenate Bio’s proprietary manufacturing system significantly reduces production costs, making their therapies accessible. Founded by experts from prestigious institutions, the company is backed by leading venture capital firms and has secured substantial non-dilutive funding to advance their mission of extending healthspan in both humans and animals.